Final answer:
The treatment protocol recommended for acute promyelocytic leukemia with M3 cytogenetic abnormality is All-trans retinoic acid (ATRA), often used in combination with an anthracycline such as daunorubicin or idarubicin.
Step-by-step explanation:
The recommended treatment protocol for acute promyelocytic leukemia (APL) with the specific cytogenetic abnormality M3 is All-trans retinoic acid (ATRA). ATRA induces differentiation of promyelocytes and is used in combination with chemotherapy, typically anthracyclines such as daunorubicin or idarubicin. This combination has significantly improved the prognosis for patients with APL. Another key drug often used in treatment protocols for other types of leukemia is cisplatin, but it is not the primary choice for APL with M3 abnormality. It is important to follow specific chemotherapy regimens designed for APL, as they have been optimized to target the unique characteristics of this type of leukemia.